100 related articles for article (PubMed ID: 16596313)
1. Circulating melatonin levels: possible link between Parkinson's disease and cancer risk?
Schernhammer E; Chen H; Ritz B
Cancer Causes Control; 2006 May; 17(4):577-82. PubMed ID: 16596313
[TBL] [Abstract][Full Text] [Related]
2. Serum melatonin is an alternative index of Parkinson's disease severity.
Lin L; Du Y; Yuan S; Shen J; Lin X; Zheng Z
Brain Res; 2014 Feb; 1547():43-8. PubMed ID: 24384141
[TBL] [Abstract][Full Text] [Related]
3. [Correlations of Melatonin and Glutathione Levels with Oxidative Stress Mechanism in Parkinson's Disease].
Wei HJ; DU M; Bai HY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Apr; 41(2):183-187. PubMed ID: 31060672
[TBL] [Abstract][Full Text] [Related]
4. Light intensity exposure, sleep duration, physical activity, and biomarkers of melatonin among rotating shift nurses.
Grundy A; Sanchez M; Richardson H; Tranmer J; Borugian M; Graham CH; Aronson KJ
Chronobiol Int; 2009 Oct; 26(7):1443-61. PubMed ID: 19916841
[TBL] [Abstract][Full Text] [Related]
5. Role of circadian rhythm and endogenous melatonin in pathogenesis of acute gastric bleeding erosions induced by stress.
Brzozowski T; Zwirska-Korczala K; Konturek PC; Konturek SJ; Sliwowski Z; Pawlik M; Kwiecien S; Drozdowicz D; Mazurkiewicz-Janik M; Bielanski W; Pawlik WW
J Physiol Pharmacol; 2007 Dec; 58 Suppl 6():53-64. PubMed ID: 18212400
[TBL] [Abstract][Full Text] [Related]
6. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle.
Davis S; Mirick DK
Cancer Causes Control; 2006 May; 17(4):539-45. PubMed ID: 16596308
[TBL] [Abstract][Full Text] [Related]
7. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
Willis GL; Robertson AD
Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
[TBL] [Abstract][Full Text] [Related]
8. Melatonin and dopamine serum level associations with motor, cognitive, and sleep dysfunctions in patients with Parkinson's disease: A cross-sectional research study.
Hadoush H; Lababneh T; Banihani SA; Al-Jarrah M; Jamous M
NeuroRehabilitation; 2020; 46(4):539-549. PubMed ID: 32538881
[TBL] [Abstract][Full Text] [Related]
9. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels.
Schernhammer ES; Kroenke CH; Dowsett M; Folkerd E; Hankinson SE
J Pineal Res; 2006 Mar; 40(2):116-24. PubMed ID: 16441548
[TBL] [Abstract][Full Text] [Related]
10. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease.
Breen DP; Nombela C; Vuono R; Jones PS; Fisher K; Burn DJ; Brooks DJ; Reddy AB; Rowe JB; Barker RA
Mov Disord; 2016 Jul; 31(7):1062-6. PubMed ID: 26971528
[TBL] [Abstract][Full Text] [Related]
11. Are some melanomas caused by artificial light?
Kvaskoff M; Weinstein P
Med Hypotheses; 2010 Sep; 75(3):305-11. PubMed ID: 20347530
[TBL] [Abstract][Full Text] [Related]
12. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease.
Bolitho SJ; Naismith SL; Rajaratnam SM; Grunstein RR; Hodges JR; Terpening Z; Rogers N; Lewis SJ
Sleep Med; 2014 Mar; 15(3):342-7. PubMed ID: 24529544
[TBL] [Abstract][Full Text] [Related]
13. Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.
Belaid H; Adrien J; Karachi C; Hirsch EC; François C
Sleep Med; 2015 Oct; 16(10):1245-51. PubMed ID: 26429753
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease.
Chen H; Schernhammer E; Schwarzschild MA; Ascherio A
Am J Epidemiol; 2006 Apr; 163(8):726-30. PubMed ID: 16495472
[TBL] [Abstract][Full Text] [Related]
15. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Willis GL; Robertson AD
Pharmacol Biochem Behav; 2004 Nov; 79(3):413-29. PubMed ID: 15582013
[TBL] [Abstract][Full Text] [Related]
16. [Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam].
Litvinenko IV; Krasakov IV; Tikhomirova OV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(12):26-30. PubMed ID: 23388588
[TBL] [Abstract][Full Text] [Related]
17. To die or grow: Parkinson's disease and cancer.
West AB; Dawson VL; Dawson TM
Trends Neurosci; 2005 Jul; 28(7):348-52. PubMed ID: 15913799
[TBL] [Abstract][Full Text] [Related]
18. Melatonin for sleep disturbances in Parkinson's disease.
Dowling GA; Mastick J; Colling E; Carter JH; Singer CM; Aminoff MJ
Sleep Med; 2005 Sep; 6(5):459-66. PubMed ID: 16084125
[TBL] [Abstract][Full Text] [Related]
19. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study.
Willis GL; Turner EJ
Chronobiol Int; 2007; 24(3):521-37. PubMed ID: 17612949
[TBL] [Abstract][Full Text] [Related]
20. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women.
Blask DE; Dauchy RT; Brainard GC; Hanifin JP
Integr Cancer Ther; 2009 Dec; 8(4):347-53. PubMed ID: 20042410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
